Additionally, the molecular mechanism underlying its anti-tumor effects was elucidated using phospho-RTK antibody arrays, confirming its ability to inhibit the phosphorylation of MET and VEGFR2 along with activation of downstream signaling pathways. The gene discussed is MET; the disease is neoplasm.